A short peptide made of just 10 amino acids forms an injectable hydrogel that delivers the chemotherapy drug paclitaxel directly to tumors and releases it slowly in response to the tumor's acidic environment.
Just 10 amino acidsOne of the shortest peptide sequences shown to form a functional, pH-responsive drug delivery hydrogel for cancer treatment
What the researchers found
The short peptide KK (sequence: KIKIDPPIKIK) has an angular structure created by its proline-proline core that enables it to form a network hydrogel under neutral pH, trapping hydrophobic paclitaxel. Under the slightly acidic conditions found in tumors, the gel structure changes and releases the drug in a sustained manner.
In vitro and in vivo experiments demonstrated that the drug-loaded hydrogel improved anti-tumor efficacy while showing good biocompatibility and biological safety. The peptide's functional properties are achieved with only 10 amino acids, making it cheaper and easier to synthesize than longer peptide-based delivery systems.
Why it matters
Many powerful chemotherapy drugs like paclitaxel are limited by poor solubility and harsh side effects when given systemically. Peptide hydrogels that respond to tumor acidity could deliver drugs locally with sustained release, reducing side effects while maintaining or improving efficacy. The fact that this works with just 10 amino acids makes it potentially practical and affordable to manufacture.
How the study worked
The peptide was synthesized using solid-phase peptide synthesis. Its structure was examined under neutral and acidic conditions using transmission electron microscopy and circular dichroism. Drug release was measured in vitro. Injectability was confirmed through rheological testing. Anti-tumor efficacy was tested in cell culture (in vitro cytotoxicity) and in tumor-bearing mice (in vivo). Biocompatibility was assessed both in cells and in animals.
What this study cannot tell us
The study was conducted in cell lines and mice, not humans. The abstract does not report specific tumor reduction percentages or survival data. Long-term stability of the hydrogel in vivo and its performance with drugs other than paclitaxel were not addressed.
How to read the evidence
This is a preclinical study with in vitro and in vivo (mouse) data. It demonstrates proof of concept for the delivery system but has not been tested in humans.
When this study was published
Published in 2025, this represents current research in peptide-based drug delivery and self-assembling biomaterials.
The bigger picture
Self-assembling peptide hydrogels are an active area of drug delivery research. This study contributes a minimalist design — achieving tumor-responsive drug release with one of the shortest peptide sequences reported. As the field moves toward clinical translation, simpler, cheaper peptide carriers like this could make targeted drug delivery more accessible.
Questions still open
- Could this peptide hydrogel system deliver other hydrophobic drugs beyond paclitaxel for different cancer types?
- How does the drug release rate compare to other peptide-based and polymer-based hydrogel delivery systems?
- What would be needed to advance this from mouse studies to human clinical trials?
Common questions
How does the peptide gel know to release the drug at the tumor?
Why is a 10-amino-acid peptide significant for drug delivery?
Read the original research
Short peptide hydrogel with angular structure for hydrophobic antitumor drug delivery and controlled release.
Colloids and surfaces. B, Biointerfaces, 254, 114793
Citation
Yao, Qingqing; Gao, Jie; Liu, Linsheng; Shi, Jinfang; Zafar, Hajra; Khan, Muhammad Ijaz; Zhu, Jianguo; Raza, Faisal; Zhu, Ying. (2025). Short peptide hydrogel with angular structure for hydrophobic antitumor drug delivery and controlled release.. Colloids and surfaces. B, Biointerfaces, 254, 114793. https://doi.org/10.1016/j.colsurfb.2025.114793